MMP9 and colorectal carcinoma: In light of the diagnostic power enhancement by combining two ubiquitous hallmarks of cancer, the second TME-based addition to PRISM was an engineered peptide substrate that samples CRC-associated MMP9 activity and releases ligand-encoded reporters into the urine through size-specific kidney concentration.